A Study to Identify Barriers to Cellular Therapies for People With Plasma Cell Disorders

Prospective Multi-Center Study to Identify Barriers to Cellular Therapies in Patients With Plasma Cell Disorders PROACT PCD

This is an observational study that will include both participants with relapsed/refractory Multiple Myeloma and their doctors. The purpose of this study is to gather information about the use of hematopoietic cell transplantation/HCT and B-cell maturation antigen /BCMS targeted chimeric antigen receptor/CAR autologous T-cell therapy.

Inclusion Criteria:

Patient

• Diagnosis of Multiple Myeloma after January 1, 2017.
• Karnofsky Performance Status > 70%
• ≥ 2 lines of prior therapy
• Anticipated to start new a line of therapy for RRMM within the next 12 months
• Age 18-80 years of age.
• English or Spanish speaking.
• Willing to provide informed consent
• Willing to perform study procedures.

Physician Investigator

• Be a Co-Investigator
• Agree to comply with study procedures

Exclusion Criteria:

Patient

• Active CNS disease
• Patients who already have a definitive plan are to be excluded